Korean companies' progress in developing COVID-19 treatment

By Moon, sung-ho | translator Alice Kang

21.12.29 09:47:32

가나다라 0

MFDS issues EUA for the use of Pfizer’s ‘Paxlovid’… to be introduced 1H this year

Shin Poong and Ildong to initiate clinical trials… key to their success depend on participant recruitment

News of the decision to introduce Pfizer’s oral COVID-19 treatment ‘Paxlovid’ in Korea from earlier this year has increased interest in the progress made in the development of oral COVID-19 treatments at Korean pharmaceutical companies.

The interest in when the homegrown oral COVID-19 treatments will be commercialized was triggered by the earlier-than-expected introduction of oral COVID-19 treatments from multinational pharmaceutical companies.

# According to the Ministry of Food and Drug Safety and industry sources on December 29th, Shin Poong Poong Pharmaceutical, Daewoong Pharmaceutical, Ildong Pharmaceutical, and Genencell are developing oral COVID-19 treatments.

T

Moon, sung-ho(news@medicaltimes.com)

If you want to see the full article, please JOIN US (click)